» Articles » PMID: 22871664

High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector

Abstract

Human immunodeficiency virus type 1 (HIV1) vectors poorly transduce rhesus hematopoietic cells due to species-specific restriction factors, including the tripartite motif-containing 5 isoformα (TRIM5α) which targets the HIV1 capsid. We previously developed a chimeric HIV1 (χHIV) vector system wherein the vector genome is packaged with the simian immunodeficiency virus (SIV) capsid for efficient transduction of both rhesus and human CD34(+) cells. To evaluate whether χHIV vectors could efficiently transduce rhesus hematopoietic repopulating cells, we performed a competitive repopulation assay in rhesus macaques, in which half of the CD34(+) cells were transduced with standard SIV vectors and the other half with χHIV vectors. As compared with SIV vectors, χHIV vectors achieved higher vector integration, and the transgene expression rates were two- to threefold higher in granulocytes and red blood cells and equivalent in lymphocytes and platelets for 2 years. A recipient of χHIV vector-only transduced cells reached up to 40% of transgene expression rates in granulocytes and lymphocytes and 20% in red blood cells. Similar to HIV1 and SIV vectors, χHIV vector frequently integrated into gene regions, especially into introns. In summary, our χHIV vector demonstrated efficient transduction for rhesus long-term repopulating cells, comparable with SIV vectors. This χHIV vector should allow preclinical testing of HIV1-based therapeutic vectors in large animal models.

Citing Articles

Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model.

Uchida N, Stasula U, Demirci S, Germino-Watnick P, Hinds M, Le A Nat Commun. 2023; 14(1):6291.

PMID: 37828021 PMC: 10570335. DOI: 10.1038/s41467-023-41153-5.


A Comprehensive Atlas of Immunological Differences Between Humans, Mice, and Non-Human Primates.

Bjornson-Hooper Z, Fragiadakis G, Spitzer M, Chen H, Madhireddy D, Hu K Front Immunol. 2022; 13:867015.

PMID: 35359965 PMC: 8962947. DOI: 10.3389/fimmu.2022.867015.


Preclinical evaluation for engraftment of CD34 cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models.

Uchida N, Li L, Nassehi T, Drysdale C, Yapundich M, Gamer J Cell Rep Med. 2021; 2(4):100247.

PMID: 33948577 PMC: 8080237. DOI: 10.1016/j.xcrm.2021.100247.


Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease.

Uchida N, Drysdale C, Nassehi T, Gamer J, Yapundich M, DiNicola J Mol Ther Methods Clin Dev. 2021; 21:121-132.

PMID: 33816645 PMC: 8005818. DOI: 10.1016/j.omtm.2021.02.022.


NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease.

de Ravin S, Brault J, Meis R, Li L, Theobald N, Bonifacino A Blood Adv. 2020; 4(23):5976-5987.

PMID: 33284949 PMC: 7724899. DOI: 10.1182/bloodadvances.2020003224.


References
1.
Imren S, Payen E, Westerman K, Pawliuk R, Fabry M, Eaves C . Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002; 99(22):14380-5. PMC: 137892. DOI: 10.1073/pnas.212507099. View

2.
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

3.
Uchida N, Washington K, Hayakawa J, Hsieh M, Bonifacino A, Krouse A . Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol. 2009; 83(19):9854-62. PMC: 2748003. DOI: 10.1128/JVI.00357-09. View

4.
Schwarzwaelder K, Howe S, Schmidt M, Brugman M, Deichmann A, Glimm H . Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest. 2007; 117(8):2241-9. PMC: 1934556. DOI: 10.1172/JCI31661. View

5.
Persons D, Allay E, Sabatino D, Kelly P, Bodine D, Nienhuis A . Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood. 2001; 97(10):3275-82. DOI: 10.1182/blood.v97.10.3275. View